Goodwin advised Blueprint Medicines (NASDAQ: BPMC), on its underwritten public offering of 4,259,259 shares of its common stock at a public offering price of $81.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Blueprint Medicines estimates net proceeds from the offering will be approximately $325.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. The company, led by Daniel S Lynch, Jeffrey W Albers and Anthony L Boral, in 2016 recorded $27.8 Million Revenues.
The Goodwin team was led by partners Danielle Lauzon (Picture) and Kingsley Taft, and included associates Yasin Akbari, Patricia Mets and Tom Murphy, and counsel Stephanie Philbin.
Law Firms: Goodwin Procter;
Clients: Blueprint Medicines;